Fifty-eight consecutive children with high-risk malignancies were treated with CY, and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a phase I/II Institutional Review Board-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of topotecan 3 mg/m 2 per day, with subsequent doses targeted to total systemic exposure of 100 ± 20 ng h/mL and CY 750 mg/m 2 per day. Seven participants received dose level 2. CY dose escalation to 1 g/m 2 per day was considered excessively toxic; one died from irreversible veno-occlusive disease and two experienced reversible hepatotoxicity. These adverse events halted further dose escalation. A total of 46 participants were enrolled in phase II; results are on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) and retinoblastoma (1). Twenty participants (39.3%) were in XCR1 at enrollment; median age was 5.1 years. Most common non-hematological grade III --IV toxicity was gastrointestinal (n ¼ 37). Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-six (51%) participants remain alive at a median of 6.4 years after AHCT. CY 3.75 g/m 2 , and targeted topotecan followed by AHCT are feasible and produce acceptable toxicity in children with high-risk malignancies. Keywords: CY; topotecan; autologous BMT; neuroblastoma; sarcoma; lymphoma INTRODUCTION Autologous hematopoietic cell transplantation (AHCT) is used as consolidation therapy to treat patients with high-risk malignancies; however, only a fraction of these patients are cured with the majority developing recurrent disease.
INTRODUCTION
Autologous hematopoietic cell transplantation (AHCT) is used as consolidation therapy to treat patients with high-risk malignancies; however, only a fraction of these patients are cured with the majority developing recurrent disease. 1, 2 Clinical and laboratory studies support dose intensification as a strategy for improving survival for adults and children with malignancies at high risk of treatment failure. In our preclinical xenograft model system, and in phase I and II trials, topotecan has shown promising anti-tumor activity in several pediatric malignancies, such as neuroblastoma, rhabdomyosarcoma, central nervous system tumors and Wilms tumor. 3 --7 Results of a Pediatric Oncology Group phase I trial identified the maximum tolerated dose (MTD) for topotecan (0.75 mg/m 2 per day) and CY (250 mg/m 2 per day) when each was given once daily for 5 consecutive days without stem cell rescue, but followed by filgrastim. 8 No significant toxicity other than myelosuppression was identified, and responses were observed in osteosarcoma, neuroblastoma, Wilms tumor and rhabdomyosarcoma. The broad anti-tumor activities of this combination in lower doses made it ideal to consider escalation to higher doses with AHCT.
Doses up to 7 g/m 2 of CY have been given in combination with maximum doses of etoposide (a topoisomerase II inhibitor) followed by stem cell rescue, with acceptable toxicity. Therefore, CY 3.75 g/m 2 combined with topotecan was considered safe for study in the setting of autologous stem cell rescue. In children with recurrent solid tumors, researchers at St Jude Children's Research Hospital in Memphis, TN, USA, completed a phase I trial of topotecan, 10 doses delivered with dose adjustments to a targeted systemic exposure of 100 ng h/mL. In another St Jude trial for metastatic neuroblastoma, researchers successfully targeted the topotecan dose in 22 of 27 days (81%), but more importantly attained the targeted topotecan area under the concentration-time curve (AUC) in each patient studied. 9 On the basis of this experience, a phase I/II dose escalation study using 10 doses of topotecan and 5 doses of CY, followed by AHCT in children with high-risk malignancies, was proposed.
MATERIALS AND METHODS
Patients with solid tumor and lymphomas at high risk of treatment failure were eligible. Additional eligibility criteria included age o25 years at diagnosis, ECOG performance score 0 --2, ANC 4750 per mm Board approved this clinical trial, and participants and/or legal guardians provided informed consent before the initiation of the preparative regimen.
Toxicity grading
Toxicities were collected prospectively by a clinical research nurse for the first 100 days after transplantation and followed for resolution; a transplant physician concurrently reviewed all toxicities and assigned level of severity and attribution to the treatment regimen. All cases of non-hematological organ dysfunction were considered regimen-related toxicities. Toxicities were scored according to the National Cancer Institute Common Toxicity Criteria Version 2.0. 10 An external Data Safety Monitoring Board was not used for this trial; rather, the study's investigators discussed and monitored the toxicities internally.
Study design and analysis
The trial was originally designed to study four dosage levels in the phase I portion of the study:
Level 1: CY dosage 3.75 g/m 2 ; targeted topotecan to 100±20 ng h/mL; Level 2: CY dosage 5 g/m 2 ; targeted topotecan to 100±20 ng h/mL; Level 3: CY dosage 5 g/m 2 ; targeted topotecan to 140 ± 20 ng h/mL; Level 4: CY dosage 5 g/m 2 ; targeted topotecan to 160 ± 20 ng h/mL.
The objectives of this trial in defining the MTD were assessed according to a traditional phase I study. MTD was defined as the dose level below the unacceptable dose-limiting toxicity level. A dose-limiting toxicity was defined as an irreversible toxicity, present at the time of death, or reversible non-hematological grade IV toxicity that persisted for greater than 10 days. Any participant who had not engrafted by day 45 posttransplantation was also considered a failure.
Once the MTD was determined, the phase II portion of the study began with the aim to better understand the toxicity profile due to this regimen. This portion of the study was set up using a Simon's two-stage design to try to ensure that few patients were on a toxic chemotherapy preparative regimen. 11 Those in the MTD cohort in phase I were included in the phase II part of the study. Although the study was originally written to enroll up to an additional 19 patients at the MTD, because stopping rules had not been met and there was no subsequent protocol for these patients, Institutional Review Board approval was obtained to continue enrollment on study. Hence, 51 participants were enrolled and treated on dose level 1.
Survival was defined as the time interval from date of transplant to death from any cause or to last follow-up. For EFS, an event was defined as a relapse, disease progression, or death (due to any cause). The date of the first event was used in calculating EFS. For this survival analysis, time was censored at the last follow-up date if no failure was observed. Kaplan --Meier survival estimates were obtained and the comparisons between survival distributions were made using the log-rank test. 12, 13 The cumulative incidence of relapse was estimated by the method of Kalbfleisch and Prentice, 14 which accounts for competing risks. The length of time at risk for relapse was computed from the date of AHCT to the date of relapse, death or last contact, whichever came first. Deaths from nonrelapse causes were considered as competing events. The cumulative incidences of relapse for different diagnosis group were compared by Gray's test. 15 The criteria for significance for all analyses were a P-value significant at a level of a ¼ 0.05. All statistical analyses used SAS Release 9.2 (SAS Institute, Inc., Cary, NC, USA).
Disease status, such as CR, very good partial response, partial response, stable disease and progressive disease, was not defined by this study. Participant's disease response was categorized as determined by the participant's induction chemotherapy.
Stem cell collection and cryopreservation
All patients had marrow morphologically free of tumor at the time of PBSC collection or marrow harvest. PBSC collection was performed after routine chemotherapy administration followed by G-CSF 10 mcg/kg per day until apheresis was completed. PBSC collection goal was at least 2 Â 10 6 CD34 þ cells per kg. A marrow harvest was performed in patients unable to mobilize stem cells; targeted marrow cell dose was greater than 1.0 Â 10 8 total nucleated cells per kg. Two patients had stem cell products purged on another institutional protocol using CD34 þ selection and FACS analysis. A minimum of 1 Â 10 6 CD34 þ cells per kg from an apheresis product or 1 Â 10 8 total nuclear cells per kg from a marrow product was required to proceed to AHCT. All stem cell products were stored at --150 1C in the vapor phase of liquid nitrogen using 10% dimethylsulfoxide and a controlled rate freeze program.
Conditioning regimen
For the phase I portion of the study, topotecan was administered i.v. once daily as a 30-min infusion for 10 days (Days --11 to --2). At levels 1 and 2, patients initially received topotecan 3 mg/m 2 per day, with subsequent dosages adjusted to achieve a targeted topotecan lactone AUC value of 100±20 ng h/mL. 16 Dosages of chemotherapeutic agents were calculated using actual body weight. All patients but one received full-prescribed doses of each agent.
On days À6 through À2, CY was infused i.v. ). Mesna at 25% of the CY dose was administered i.v. before each dose of CY and again at 3, 6 and 9 h after each dose of CY, equaling 100% of the CY dose. At level 2, CY was administered at a dose of 1000 mg/m 2 per day for 5 days (total 5 g/m 2 ). Patients began pre-hydration with D5W þ 0.45% sodium chloride at 125 mL/m 2 /h at the time of admission to the inpatient transplant unit on day À7, the evening before the first dose of CY. This i.v. fluid rate continued until day 0, the day of the stem cell infusion. Day --1 was a rest day. Before stem cell infusion on day 0, the graft was rapidly thawed in a 37 1C water bath at the bedside and then infused through a central venous catheter. On day þ 1, G-CSF was given at 5 mg/kg per day s.c. or i.v. until ANC 43000 per mm 3 on 2 consecutive days. No prophylaxis for venoocclusive disease of the liver was administered.
Pharmacokinetics
For each patient, blood samples were obtained before the topotecan infusion, and at 0.25, 1 and 6 h after the end of the topotecan infusion on days À6 and À11. Each sample was processed immediately, and topotecan lactone concentrations were measured by HPLC. 16 Topotecan lactone systemic clearance and single-day AUC were calculated for each patient. If the single-day topotecan lactone AUC was within the targeted AUC range on day À11 or day À6, then no dosage adjustment was required on the subsequent day, and the patient remained at the same topotecan dosage. If the single-day topotecan lactone AUC was not within the targeted topotecan AUC range on day À11 or day À6, the subsequent topotecan dosage was adjusted on the basis of that patient's topotecan lactone clearance, to attain a single-day topotecan lactone AUC in the targeted range.
If the topotecan target AUC range was not achieved with the dosage adjustment on day À10 or À5, additional dosage adjustments were made until the target was achieved. If topotecan blood samples or pharmacokinetic studies were not evaluable, then blood samples were obtained on the next available day. Dose adjustment followed the same procedure as outlined above.
RESULTS

Patient characteristics
Fifty-eight patients with high-risk solid malignancies were enrolled on this Institutional Review Board-approved study. Twelve patients received therapy on the phase I portion. Five received dose level 1 (topotecan target AUC of 100±20 ng h/mL and CY 750 mg/m 2 per day Â 5 days). One of the five participants experienced a dose-limiting toxicity, stomatitis. Seven patients were treated at dose level 2 (topotecan target of 100 ± 20 ng h/mL and CY 1000 mg/m 2 per day Â 5 days). One dose level 2 patient experienced an irreversible grade IV non-hematological regimen-related toxicity and eventually died of veno-occlusive disease. Two other participants experienced grade 2 hyperbilirubinemia and were clinically diagnosed with mild veno-occlusive disease. Although these two events did not meet stopping rule guidelines, for the safety of the patients, the principal investigator in collaboration with other study team members, including the study's biostatistician and co-investigators, decided to close the phase I safety portion of the study. Dose level 1 was deemed the MTD. Characteristics dose level 2 participants are described in Table 1 . Three participants died from primary disease. The next 46 consecutive patients were treated on the trial's phase II portion at dose level 1. Results will be described on the basis of the 51 patients who received therapy at dose level 1 (5 from phase I and 46 from phase II). Patient demographics for these participants, including diagnoses, disease status at the time of AHCT are outlined in Table 2 .
Regimen-related toxicities A total of 50 of the 51 participants were able to receive full doses of the preparative regimen. One patient with non-Hodgkin lymphoma was only able to received 9 of 10 doses of topotecan and 3 of 5 doses of CY. This participant developed premature ventricular contractions with short runs of ventricular tachycardia, and further chemotherapy was omitted. The patient, who had no previous history of cardiac disease and had a normal echocardiogram and electrocardiography before the initiation of this therapy, remained hemodynamically stable, had no electrolyte abnormalities, and did not require medical intervention. Although there was also a high incidence of other grade III --IV toxicity in this heavily pretreated population (Table 3) , three patients had no grade III --IV non-hematological toxicity. Toxicities were reviewed in real time at transplant research meetings and determined to be acceptable, and expected in the setting of high-dose chemotherapy followed by stem cell rescue, particularly gastrointestinal toxicities (Table 4) . Because of these expected toxicities, de-escalation below level 1 was not considered. Three patients (5.9%) died of non-relapse toxicity, including multi-system organ failure and respiratory failure.
Transplant outcome All patients achieved neutrophil engraftment, defined as the first day of 3 consecutive days with an ANC 40.5 Â 10 9 per L, at a median of day þ 15 (range, 8 --33 days) and platelet engraftment, defined as platelets 420 000 per mL without transfusion for 7 consecutive days, at a median of day þ 24 (range, 8 --109 days). The median time to neutrophil engraftment for patients receiving marrow grafts was day þ 18 (range, 10 --33 days) and for those receiving PBSC grafts day þ 10 (range, 8 --11 days; Po0.0001). The median time to platelet engraftment for marrow recipients was day þ 27 (range, 16 --109 days), whereas those receiving PBSC grafts achieved platelet engraftment at a median of day Hyperbilirubinemia was determined to be a DLT by the study's principal investigator, in collaboration with study co-investigators, biostatisticians and other team members. diagnoses, P-value ¼ 0.83; Figure 2b ), neuroblastoma (the most common tumor in this study) showed a tendency of being more likely to relapse at both 3 and 5 years (57.7±10.0 and 61.5±9.9%, respectively) compared with lymphomas (50.0 ± 19.4 and 50.0 ± 19.4%, respectively) or sarcomas (44.4 ± 17.9 and 44.4 ± 17.9%, respectively). Upon univariate analysis of OS and EFS with respect to gender, product infused, diagnosis and disease status before AHCT, none of these variables were statistically significant (data not shown). Twenty-two patients (43.2%) died of recurrent, persistent or progressive disease; two (3.9%) died from multi-organ failure, and one (2%) died from respiratory failure. Twenty-six participants (51%) are alive at a median follow-up time of 6.4 years (range, 4.0 --9.8 years).
Pre-and post-transplant therapy Four patients received radiation therapy before AHCT, four received radiation after AHCT, and five received radiation therapy both before and after AHCT. Three patients with neuroblastoma received post-transplant therapy with cis-retinoic acid, beginning at a median of 32 days post-AHCT (range, 32 --53 days) and continuing for 6 months as directed by their primary treatment plan. No patient received anti-tumor Ab therapy post-HSCT.
Topotecan pharmacokinetics
The median (range) topotecan lactone clearance was 32.1 L/h/m 2 (range, 15.3 --44.2). A total of 138 pharmacokinetic studies were performed in 55 patients during cycle 1. All patients received a fixed 3 mg/m 2 fixed topotecan dosage for the first dose of cycle 1, and of the 55 studies, 39 (71%) were within the desired target range. Of the remaining 83 pharmacokinetic studies, 67 were within the target range for a pharmacokinetic targeting success of 81%. The median (range) topotecan dosage for the patients that were within the target range was 3.1 mg/m 2 (1.1 --4.6). Those studies outside the target range were evenly distributed among participants, and after a second study, all patients were within the The relationship of the adverse event to the study was defined as definite, possible, probable, or remote. The numbers in the cells represent the number of participants who experienced this maximum grade adverse event and the total number of participants who experienced an adverse event in the specific category. Adverse events were coded according to the Common Toxicity Criteria, version 2.0. 
DISCUSSION
In the past 25 years, the prognosis for pediatric solid tumors has improved largely, because of a multi-modal approach, including multi-agent chemotherapy regimens, aggressive surgery and conformal radiation therapies. However, patients with metastatic or recurrent disease often have a dismal prognosis and are candidates for aggressive therapy including AHCT. Although neuroblastoma is the only pediatric malignancy in which Abdominal pain  6  0  Headache  1  0  Pain, back  1  0  Pain, generalized, multiple sites  3  0  Pain, skin  1 Figure 1 . OS and EFS of the 51 participants and the number at risk treated on dose level 1. randomized studies have demonstrated an increase in survival rate with the addition of AHCT to the treatment schema compared with standard chemotherapy alone, this treatment is frequently used to treat other high-risk pediatric solid tumors, such as Ewing sarcoma, rhabdomyosarcoma, Wilms tumor and lymphomas. 17 --21 Topotecan has shown promising anti-tumor activity in pediatric malignancies, such as neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma and Ewing sarcoma. 22 --24 In a Children's Oncology Group trial in which 119 patients with relapsed or refractory neuroblastoma were randomized to receive either topotecan alone (2 mg/m 2 per day for 5 days) or in combination with CY (topotecan 0.75 mg/m 2 per day with CY 250 mg/m 2 per day for 5 days), the two-drug combination demonstrated superior outcomes in terms of PFS, but no difference in OS. 3 Combining alkylating agents with topoisomerase inhibitors is attractive, because of the broad activity in pediatric malignancies and the non-overlapping extramedullary toxicities. Gastrointestinal, fever/neutropenia, metabolic disturbances and skin abnormalities were the most common grade III --IV toxicities observed. Skin toxicities were common in areas that had received prior radiation therapy, as well as in non-radiated regions. 25 Topotecan is known to be a radiosensitizing agent, suggesting these skin toxicities were a form of radiation recall. 26, 27 Of the patients who had received thoracic radiation therapy, one developed cardiac arrhythmias and another pleuro-pericardial effusions.
Three patients died of non-relapse causes, including multisystem organ failure and single organ failure. This toxicity rate is lower compared with those reported in other series of AHCT in pediatrics. 28 The remainder of those who died in this trial experienced progressive or recurrent disease. This is consistent with the results of prior studies in which disease recurrence has remained the main cause of treatment failure after AHCT. 29 Venoocclusive disease and liver toxicity have not been observed frequently with topotecan, but was the most common toxicity leading to the determination of the MTD. 30, 31 CY may have also contributed to the observed hepatotoxicity as this side effect has been well described, 32, 33 and the participants were heavily pretreated before AHCT. Topotecan, on the other hand, has not been studied extensively as a component of transplant regimens. The majority of published experience is in the setting of high-risk or recurrent ovarian cancer or multiple myeloma, used in combination with other agents. 34 --37 For patients with central nervous system tumors, topotecan (2 mg/m 2 per day for 5 days) was given with thiotepa (300 mg/m 2 per day for 3 days) and carboplatin (approximating 500 mg/m 2 per dose for 3 days, with Calvert formula under the curve 7) to 10 patients. 38 There were two toxic deaths and four were surviving disease-free at a median of 6 years after treatment. Other trials using topotecan-containing regimens, with and without stem cell support, demonstrate feasibility and therapeutic efficacy in patients with leukemias, lymphomas, and other solid tumors in children and adults. 39 --44 These studies have demonstrated acceptable response rates to the treatment regimen. Toxicities in these studies were similar to ours, but cutaneous toxicity was not commonly observed. It is important to note that this study was the only one to target topotecan doses and the only one to include pediatric patients. Other published studies primarily included adult patients with non-pediatric malignancies, a markedly different population than this study.
Five-year EFS for all patients on this study was 41.2%, which compares favorably with the literature, as these were high-risk diseases. Mesenchymal tumors, such as sarcomas, had promising results with the 5-year EFS being 44.4%, suggesting this regimen merits further study in this cohort. In addition, patients with lymphoma demonstrated responses (5-year EFS 50%), but patient numbers were quite low. Additional studies are needed in this group to better categorize efficacy. For patients with neuroblastoma, it is important to note that none of these patients received post-transplant Ab therapy. OS rates at 5 years were favorable, allowing patients to proceed to other salvage therapies. This observation suggests that this regimen is well tolerated and does not lead to long-term organ dysfunction and prohibiting further relapse therapies.
In this study, the MTD dose was determined to be 3 g/m 2 CY and 10 doses of topotecan with a targeted systemic exposure of 100±20 ng h/mL when administered with hematopoietic stem cell rescue. Topotecan was easily administered on an outpatient basis, although early admissions were necessary because of fever in some patients. Our study demonstrates the feasibility and relative safety of this combination of CY and topotecan. Future efforts may be directed at increasing the dose of topotecan or incorporating an additional agent into the regimen. As has been demonstrated in other malignancies, most notably ALL, individualized drug treatment may enhance treatment efficacy while reducing toxicity. 45, 46 
